<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:contributor>Niels Lorenzen</dc:contributor>
  <dc:contributor>S. E. LaPatra</dc:contributor>
  <dc:contributor>C.A. Grady</dc:contributor>
  <dc:contributor>S.E. Roon</dc:contributor>
  <dc:contributor>J. O’Reilly</dc:contributor>
  <dc:contributor>J.L. Gregg</dc:contributor>
  <dc:contributor>P.K. Hershberger</dc:contributor>
  <dc:creator>L.M. Hart</dc:creator>
  <dc:date>2012</dc:date>
  <dc:description>&lt;p&gt;Viral haemorrhagic septicaemia virus (VHSV) and its associated disease state, viral haemorrhagic septicaemia (VHS), is hypothesized to be a proximate factor accounting for the decline and failed recovery of Pacific herring populations in Prince William Sound, AK (Marty et al. 1998, 2003, 2010). Survivors of laboratory-induced VHSV epizootics develop resistance to subsequent viral exposure (Kocan et al. 2001; Hershberger et al. 2007, 2010), which is likely the result of immune system recognition of the viral glycoprotein (G) (Lecocq-Xhonneux et al. 1994), a surface antigen that contains neutralizing epitopes (Lorenzen, Olesen &amp;amp; Jorgensen 1990; J&amp;oslash;rgensen et al. 1995) and cell attachment domains (Lecocq-Xhonneux et al. 1994; Estepa &amp;amp; Coll 1996). These properties have proven useful in the development of G-gene-based DNA vaccines for VHSV and a related rhabdovirus, infectious haematopoietic necrosis virus (IHNV) (Anderson et al. 1996; Heppell et al. 1998; Corbeil et al. 1999; Einer-Jensen et al. 2009). Rainbow trout fingerlings, &lt;i&gt;Oncorhynchus mykiss&lt;/i&gt; (Walbaum), vaccinated with 1 &amp;micro;g of either the VHS or IHN vaccine are protected from VHS when exposed to virus as early as 4 days (44 degree days) post-vaccination (p.v.) (Lorenzen et al. 2002). At later time points (80 days p.v.; 880 degree days), the level of cross-protection against VHS by IHN vaccination is either completely lost (60 days p.v.; 660 degree days) (3 g rainbow trout; 1 &amp;micro;g vaccine dose) (Lorenzen et al. 2002) or present at intermediate levels (6.5 g rainbow trout; 1 &amp;micro;g vaccine dose) (Einer-Jensen et al. 2009). Comparatively, VHS vaccination remains effective as long as 9 months (2520 degree days) p.v. (100 g rainbow trout; 0.5 &amp;micro;g vaccine dose) (McLauchlan et al. 2003). These results suggest that IHN and VHS vaccination activate a rapid transitory innate immune response against VHSV that is followed by long-term adaptive immunity in VHS-vaccinated trout (Lorenzen et al. 2002).&lt;/p&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>10.1111/j.1365-2761.2012.01364.x</dc:identifier>
  <dc:language>en</dc:language>
  <dc:publisher>Blackwell Science</dc:publisher>
  <dc:title>Efficacy of a glycoprotein DNA vaccine against viral haemorrhagic septicaemia (VHS) in Pacific herring, &lt;i&gt;Clupea pallasii&lt;/i&gt; Valenciennes</dc:title>
  <dc:type>article</dc:type>
</oai_dc:dc>